Event Participants
Executives
3 Dr. Devlina Chakravarty, Rudra Narain Acharya, Sanjeev Kothari
Analysts
11 Aadesh Gosalia, Abin Benny, Aditya Chheda, Anubhav Sangal, Kumar Saurabh, Nandakumar, Neelam Punjabi, Sanidhya Agarwal, Sridhar Parthasarathy, Sumit Gupta, Vedant Nilekar
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹287.35 crores | +12.7% YoY; standalone Gurgaon grew 15.4% YoY, driven by demand across Cardiology, Oncology, Neurosciences and Orthopedics plus improved case mix |
| Operational Beds (Gurgaon) | ~700 beds | Maintained during quarter; management flagged inflection point requiring 200+ additional beds to prevent patient denial |
| Occupancy | 65.7% | Management guided to ~70% by Q2 FY27; on track per management |
| ARPOB | ₹85,690 | Continued improvement driven by case mix shift toward complex quaternary procedures; among the highest in Delhi-NCR |
| International Patient Mix | 27% of revenue | Slightly lower than ~30% typical; resilient despite West Asian war disruptions with 12–15% top-line movement sustained |
| EBITDA | ₹61.78 crores | Margin of 21.5%; driven by economies of scale, case mix improvement, manpower cost optimization, and reduced average length of stay |
| PAT | ₹31.56 crores | +48.9% YoY; reflects operating leverage and strength of the Gurgaon flagship (95–97% of revenues) |
| Cost-to-Income | Not disclosed | Efficiency gains cited from optimized manpower, consumption control, and shorter length of stay |
Table Rules:
- Order metrics logically: Deposits → Assets → Asset Quality → Profitability → Margins → Capital
Given this is a hospital company, the ordering is adapted: Revenue → Beds → Occupancy → ARPOB → International mix → EBITDA → PAT.
Geographic & Segment Commentary
Gurgaon Flagship Hospital: Delivered 15.4% standalone top-line growth with occupancy at 65.7% and ARPOB of ₹85,690. Contributes 95–97% of consolidated revenue. Management cited economies of scale, superior case mix, and operational efficiencies as margin drivers; EBITDA margin of 21.5% expected to remain at 20–21% in FY27 and reach 23–24% over 2–3 years.
Raipur (Artemis Shanthi Hospital): 300-bed multi-specialty tertiary care hospital commenced soft launch on July 9 (OPD) with operating theaters and cath lab operational July 27–28. All services launched together including onco surgery (commando procedure performed within first week), advanced cath lab, EP systems, and neurosurgery. PET-CT and radiotherapy unit installations pending by end of August. INR120 crores capex, 80% already spent. Breakeven expected in 15–18 months with ~₹20 crores cumulative operating loss.
International Business: International patient mix at 27% of revenue despite West Asian war, with growth from Middle East, Africa, CIS markets. No single-region dependency; 2–3 new international catchment fronts added annually. Management expects mix closer to 30% in Q2 FY27.
Daffodils / Artemis Lite / Cardiac Care: Small-format centers face capacity constraints; served as hub-and-spoke feeders for the flagship. Management indicated consolidation into larger units or hospital wings to improve EBITDA efficiency, while expanding hub-and-spoke into new geographies like Raipur.
Company-Specific & Strategic Commentary
Tower 4 (Gurgaon): 200+ bed expansion (as per layouts, total operational beds to reach 950–980) focused on advanced tertiary/quaternary pediatric care and advanced gynecological/obstetrics. Combines ~130–150 beds from Platinum Green Building FAR benefit plus ~70 beds from purchased additional FAR following regulatory height rule changes. Capex ~₹120 crores including 450 additional parking spaces (₹55 lakhs per bed). Timeline: 18–22 months from clearances; break-even expected in 8–10 months post-launch with 50% utilization in first 6 months.
QIP Enabling Resolution: ₹700 crores approved by shareholders; wait for asset finalization targeted in 6–8 months. Proceeds earmarked for brownfield acquisitions with close-to/positive EBITDA, not announced projects. Management emphasized minimum dilution and MAX return on investment as guiding principles.
Three-Year Capex Plan: Total ₹800 crores covering Raipur (₹120 crores), VIMHANS (₹350–360 crores excluding deposit), Tower 4 (₹120 crores), and replacement capex (₹100–120 crores). VIMHANS deposit of ₹250 crores (₹130 crores already paid) is over and above this, funded from remaining IFC proceeds as deposits cannot be serviced through debt.
Strategic Bed Expansion: Combined Gurgaon, Raipur, and planned South Delhi (VIMHANS) projects to deliver 2,000 operational beds by 2029–30. Management confident of ₹2,000 crores top-line potential from Gurgaon facility alone at 85% census, 70% optimum occupancy, and 4–5% ARPOB growth over 3–5 years.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Gurgaon EBITDA Margin | 20–21% in FY27; 23–24% in 2–3 years | Driven by economies of scale (200+ bed addition), case mix improvement, and cost efficiencies |
| Gurgaon Occupancy | ~70% by Q2 FY27 | On track per management; nearing capacity inflection point |
| Tower 4 (Gurgaon) | Operational in 18–22 months; break-even in 8–10 months; 50% utilization within 6 months | Brownfield advantage—basement/podium already constructed; requires only vertical construction |
| Raipur Break-even | 15–18 months; ~₹20 crores operating loss | All services launched simultaneously; insurance empanelment expected in 8–10 weeks aided by CII common platform initiative |
| QIP | Unutilized for 6–8 months; enabling only | Depends on brownfield asset finalization; quality of asset, dilution, and ROI-based decision |
| Total Bed Capacity | 2,000 operational beds by 2029–30 | Gurgaon + Raipur + South Delhi (VIMHANS) pipeline |
| Capex | ₹800 crores over FY27–FY29 | Excludes VIMHANS deposit (₹250 crores); funded through internal accruals (~₹450 crores) + debt + equity as needed |
Risks & Constraints
| Risk | Context |
|---|---|
| Patient Denial Capacity Constraint | At 65.7% occupancy, Gurgaon approaching capacity; management acknowledged the need to add 200 beds to avoid turning away patients. Tower 4 timeline of 18–22 months creates window where denial risk persists. |
| West Asian Geopolitical Disruption | International patients contribute 27% of revenue; war caused flight suspensions regionally. Mitigated by diversified country mix and 2–3 new fronts added annually, but further escalation remains a downside risk to the mix (target ~30%). |
| Raipur Ramp-up Execution | New hospital with simultaneous launch of all services; insurance empanelment pending for 8–10 weeks (interim TPA arrangements in place). PET-CT/radiotherapy installations pending. Breakeven assumption of 15–18 months carries operational risk. |
| QIP Dilution | ₹700 crores enabling resolution could dilute existing shareholders; management reiterated commitment to minimum dilution and brownfield, EBITDA-positive assets. Internal accruals (~₹150 crores/year) plus debt cover announced projects but not new acquisitions. |
| VIMHANS Deposit Funding | ₹250 crores deposit due this fiscal (₹130 crores paid); funded from remaining IFC proceeds. Management noted deposits cannot be serviced through debt, creating finite cash constraints. |
| Competitive Intensity in Gurgaon | Rainbow Children's expanding mother-and-child capacity in the micro-market competes directly with Tower 4 positioning; management countered with superior track record in pediatric tertiary/quaternary outcomes. |
Q&A Highlights
International Patient Mix and Resilience
- Question: International patient mix has declined slightly; what is the outlook? (Aditya Chheda - InCred Asset Management)
- Answer: Mix at 27% despite West Asian war; volume in real terms maintained with 12–15% top-line growth. No regional dependency; 2–3 new international fronts added annually. Expect ~30% or better in Q2 FY27. (Devlina Chakravarty)
Tower 4 Expansion, FAR, and Timeline
- Question: Is the 200-bed expansion linked to regulatory changes allowing higher FAR, and what are timelines? (Aditya Chheda - InCred Asset Management)
- Answer: Combination of Platinum Green Building FAR (130–150 beds free) plus ~70 beds from purchased additional FAR following height/vertical construction rule change. Fully utilizing permitted FAR. Timeline 18–22 months to operationalize. (Devlina Chakravarty)
Margin Trajectory and Drivers
- Question: Can Gurgaon margins reach 23–24% in 2–3 years and what drove the strong consolidated margin? (Sumit Gupta - Antique Stock Broking; Aadesh Gosalia - Spark PWM)
- Answer: Yes, 23–24% achievable. Three key drivers: economies of scale (same cost, more patients), case mix improvement (ARPOB among highest in Delhi-NCR), and smaller center contributions. Cardiac care now PAT-positive though small; Gurgaon contributes 95–97% of revenue. (Devlina Chakravarty)
Raipur Ramp-up and Loss Guidance
- Question: What traction and loss guidance for Raipur? (Sumit Gupta - Antique Stock Broking)
- Answer: Soft launch July 9 (OPD), theaters/cath lab July 27–28. Encouraging initial footfall; complex commando onco surgery performed within first week. Break-even in 15–18 months with ~₹20 crores total operating loss. Detailed metrics to be shared in Q2 call. (Devlina Chakravarty)
Tower 4 Speciality Positioning and Margins
- Question: What specialities will Tower 4 host and expected incremental margins? (Aadesh Gosalia - Spark PWM)
- Answer: Advanced tertiary/quaternary pediatrics (heart surgery, liver/bone marrow transplants, orthopedics, endocrinology, gastroenterology) plus gynecology/obstetrics consolidated under one roof. Positioning as nodal referral center for Haryana/NCR. Margins same-to-better; economies of scale push overall margins beyond 21%. (Devlina Chakravarty)
QIP Timing, Use of Proceeds, and Dilution Management
- Question: When will the ₹700 crore QIP happen and is it prudent given IFC funds remain unspent? (Nandakumar - Shareholder; Kumar Saurabh - Scientific Investing)
- Answer: Enabling resolution only; 6–8 months for asset finalization. Remaining IFC funds will be deployed as VIMHANS deposit this fiscal (deposits can't be serviced through debt). Decision on amount raised based on asset quality, dilution minimization, and ROI. Internal accruals (~₹150 crores/year for 3 years) plus debt cover the ₹800 crores announced capex. (Devlina Chakravarty; Rudra Narain Acharya)
Capex Breakdown and Funding
- Question: What is the ₹800 crore capex composition and does it include the VIMHANS deposit? (Anubhav Sangal - Anand Rathi; Aditya Chheda - InCred)
- Answer: Breakdown: Raipur ₹120 crores, VIMHANS ₹350–360 crores (excluding deposit), Tower 4 ₹120 crores, replacement capex ₹100–120 crores. Deposit of ₹250 crores (₹130 crores paid) is over and above. Tower 4 capex at ₹55 lakhs per bed including 450 parking spaces. (Rudra Narain Acharya)
Raipur Insurance Empanelment and Services
- Question: What is the status of services and insurance empanelment at Raipur? (Vedant Nilekar - ICICI Securities)
- Answer: All services launched simultaneously (cath lab, EP, neuro, onco surgery); only PET-CT and radiotherapy pending installation by end-August. Full insurance empanelment expected in 8–10 weeks, accelerated by CII common provider-payer platform (co-chaired by Dr. Chakravarty with IRDA). Intermediary cashless claims arrangement in place meanwhile. (Devlina Chakravarty)
Tower 4 Bed Count and Ramp-up
- Question: Is the bed count 900, 950 or 1,000, and by when will it ramp up? (Sanidhya Agarwal - Unicorn Assets; Kumar Saurabh - Scientific Investing)
- Answer: Currently 700 operational beds; with 200+ addition, total between 950–980 (exact pending architectural drawings). Timeline 18–22 months; break-even in 8–10 months post-launch; 50% utilization in first 6 months. (Rudra Narain Acharya; Devlina Chakravarty)
Daffodils Strategy and Consolidation
- Question: How is Daffodils performing vs. peers like Cloudnine and what is the plan? (Sridhar Parthasarathy - Bluehill Capital)
- Answer: Hub-and-spoke model working; capacity constraints mean consolidation into larger units or hospital wings for EBITDA efficiency. Focus remains tertiary/quaternary care requiring large hospitals with operating leverage. Model to be replicated in Raipur with consolidation as centers mature. (Devlina Chakravarty)
Competitive Positioning vs. Pediatric Standalone Hospitals
- Question: How will Tower 4 compete with Rainbow Children's expansion in Gurgaon? (Vedant Nilekar - ICICI Securities)
- Answer: Artemis already performs more advanced pediatric services (heart/liver/bone marrow transplants) than standalone pediatric hospitals. Tower 4 is a positioning strategy to showcase existing strengths under one dedicated tower; trust and outcomes track record across 19 years are differentiators. (Devlina Chakravarty)
Long-term Top-line and Margin Potential
- Question: Can Gurgaon reach ₹2,000 crores top-line at 85% census with 4–5% ARPOB growth, and what margins? (Neelam Punjabi - Perpetuity Ventures)
- Answer: Yes, achievable. Margins upward of 23% at that scale given brownfield operating leverage. (Devlina Chakravarty)
Key Takeaway
Artemis Medicare delivered a strong Q1 FY27 with consolidated revenue of ₹287.35 crores (+12.7% YoY), EBITDA of ₹61.78 crores (21.5% margin), and PAT of ₹31.56 crores (+48.9% YoY), driven by Gurgaon operating leverage, case mix improvement, and an ARPOB of ₹85,690 at 65.7% occupancy. The quarter marked the operational launch of Artemis Shanthi Hospital, Raipur (300 beds), with all services (including advanced cath lab and onco surgery) live since late July and break-even guided for 15–18 months with ~₹20 crores cumulative loss. Strategic expansion accelerated with Tower 4 (200+ beds, ₹55 lakhs/bed capex, ₹120 crores total) targeting advanced pediatrics and gynecology, positioning Artemis as the NCR referral center; combined with VIMHANS/South Delhi, total capacity reaches 2,000 beds by 2029–30. A ₹700 crore QIP enabling resolution (6–8 months away) earmarked for brownfield EBITDA-positive acquisitions, with management committing to minimum dilution. Margins guided to 23–24% in 2–3 years and occupancy to ~70% by Q2 FY27; key watch points remain Raipur ramp-up execution, international patient mix resilience amid the West Asian war, and competitive intensity from standalone pediatric hospitals in the Gurgaon micro-market.